ABSTRACT
Rituximab is a B-cell depleting monoclonal antibody targeting CD20. Data concerning the behavior of psoriatic disease following rituximab therapy are extremely limited. In this report, the clinical course of a patient with established psoriasis who received rituximab therapy for vasculitis associated with mixed cryoglobulinemia (MC) type II is described. In addition to marked improvement in MC manifestations, modest improvement in psoriatic lesions also was observed following therapy. The literature concerning B-cell depletion in the setting of psoriatic disease is briefly reviewed.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Cryoglobulinemia/drug therapy , Psoriasis/drug therapy , Antibodies, Monoclonal, Murine-Derived/pharmacology , B-Lymphocytes/immunology , Cryoglobulinemia/complications , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Male , Middle Aged , Psoriasis/complications , Rituximab , Treatment Outcome , Vasculitis/drug therapy , Vasculitis/etiologyABSTRACT
The association of inflammatory myopathies with malignancy and interstitial lung disease has been well accepted. Polymyositis can be associated with interstitial lung disease or malignancy, although it is rare for all three entities to occur simultaneously at the initial presentation. We report a patient who was found to have concurrent polymyositis, interstitial lung disease, with anti-Jo-1 antibody, and renal cell carcinoma.
